Immunic Targets Multiple Sclerosis Market with Positive Phase 3 Data and Long-Term Clinical Study Results
ByAinvest
Saturday, Jan 10, 2026 12:16 pm ET1min read
IMUX--
Immunic Inc's CEO, Dr. Daniel Vitt, highlighted the significance of the Phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with progressive multiple sclerosis. The study also showed a 34% reduction in those without baseline gadolinium lesions, indicating a potential neuroprotective effect of vidofludimus calcium. Long-term results from the EMPhASIS study further support the drug's potential, with 92.3% of relapsing-remitting MS patients remaining free of 12-week confirmed disability worsening after 144 weeks.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet